Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical, Sciences, Kermanshah, Iran
Zistmavad Pharmed Co., Tehran, Iran
Curr Drug Deliv. 2020;17(5):375-386. doi: 10.2174/1567201817666200415111755.
The passage of therapeutic molecules across the Blood-Brain Barrier (BBB) is a profound challenge for the management of the Central Nervous System (CNS)-related diseases. The ineffectual nature of traditional treatments for CNS disorders led to the abundant endeavor of researchers for the design the effective approaches in order to bypass BBB during recent decades. Cell-Penetrating Peptides (CPPs) were found to be one of the promising strategies to manage CNS disorders. CPPs are short peptide sequences with translocation capacity across the biomembrane. With special regard to their two key advantages like superior permeability as well as low cytotoxicity, these peptide sequences represent an appropriate solution to promote therapeutic/theranostic delivery into the CNS. This scenario highlights CPPs with specific emphasis on their applicability as a novel theranostic delivery system into the brain.
治疗分子穿过血脑屏障（BBB）是管理中枢神经系统（CNS）相关疾病的巨大挑战。传统的 CNS 疾病治疗方法效果不佳，促使研究人员在最近几十年中大量努力设计有效的方法来绕过 BBB。细胞穿透肽（CPP）被发现是治疗 CNS 疾病的一种很有前途的策略。CPP 是具有跨生物膜转运能力的短肽序列。这些肽序列具有优越的通透性和低细胞毒性等两个关键优势，代表了促进治疗/治疗药物递送到中枢神经系统的一种合适的解决方案。这种情况突出了 CPP 的应用，特别是将其作为一种新型治疗药物传递到大脑的系统。
